

FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT

Name of Listed Issuer: Entheon Biomedical Corp. (the "Issuer").

Trading Symbol: ENBI

Date: December 3, 2020

1. New Options Granted:

Date of Grant: December 3, 2020

Position (Director/ Officer/ Employee/ Consultant/ Management Company)	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Director/Officer	Yes	200,000	\$0.71	Dec 3, 2025	N/A
Officer	Yes	575,000	\$0.71	Dec 3, 2025	N/A
Director	Yes	200,000	\$0.71	Dec 3, 2025	N/A
Director/Officer	Yes	575,000	\$0.71	Dec 3, 2025	N/A
Director	Yes	250,000	\$0.71	Dec 3, 2025	N/A
Officer	Yes	125,000	\$0.71	Dec 3, 2025	N/A
Consultant	No	150,000	\$0.71	Dec 3, 2025	N/A
Consultant	No	50,000	\$0.71	Dec 3, 2025	N/A
Consultant	No	100,000	\$0.71	Dec 3, 2025	N/A
Investor Relations	No	150,000	\$0.71	Dec 3, 2025	N/A
Consultant	No	100,000	\$0.71	Dec 3, 2025	N/A
Consultant	No	50,000	\$0.71	Dec 3, 2025	N/A
Consultant	No	100,000	\$0.71	Dec 3, 2025	N/A
Consultant	No	200,000	\$0.71	Dec 3, 2025	N/A
Consultant	No	250,000	\$0.71	Dec 3, 2025	N/A
Consultant	No	100,000	\$0.71	Dec 3, 2025	N/A

Total Number of optioned shares proposed for acceptance: 3,175,000

FORM 11 – NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Other Presently Outstanding Options: N/A

Name of Optionee	No. of Optioned Shares⁽¹⁾	Exercise Price	Original Date of Grant	Expiry Date

(1) Set out number of optioned shares for each grant with different terms.

3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

N/A

- (b) State the date of the news release announcing the grant of options.

December 4, 2020

- (c) State the total issued and outstanding share capital at the date of grant or amendment.

40,433,298

- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

7.9%

- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

868,330

- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

\$0.48

- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

N/A

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated: December 3, 2020

Brandon Schwabe
Name of Director or Senior
Officer

"Brandon Schwabe"
Signature

CFO
Official Capacity